- Clinical Trials
- February 2021
- 497 Pages
Global
From €2410EUR$2,500USD£2,061GBP
- Clinical Trials
- December 2019
- 181 Pages
Global
From €2410EUR$2,500USD£2,061GBP
- Report
- February 2022
- 80 Pages
Global
From €1928EUR$2,000USD£1,649GBP
- Report
- April 2019
- 88 Pages
Global
From €3133EUR$3,250USD£2,680GBP
- Report
- February 2024
- 96 Pages
Global
From €3500EUR$3,889USD£3,098GBP
- Report
- February 2024
- 91 Pages
Global
From €3500EUR$3,889USD£3,098GBP
- Report
- May 2022
- 51 Pages
Global
From €1928EUR$2,000USD£1,649GBP
- Report
- May 2022
- 70 Pages
Global
From €1928EUR$2,000USD£1,649GBP
- Report
- May 2022
- 49 Pages
Global
From €1928EUR$2,000USD£1,649GBP
- Report
- May 2022
- 61 Pages
Global
From €1928EUR$2,000USD£1,649GBP
- Drug Pipelines
- June 2021
- 760 Pages
Global
From €2410EUR$2,500USD£2,061GBP
- Drug Pipelines
- August 2020
- 631 Pages
Global
From €1928EUR$2,000USD£1,649GBP
- Book
- January 2010
- 616 Pages
The Heart Failure Drug market is a subset of the Cardiovascular Drugs market, which includes drugs used to treat a variety of heart-related conditions. Heart Failure Drugs are used to treat heart failure, a condition in which the heart is unable to pump enough blood to meet the body's needs. These drugs can help reduce symptoms, improve quality of life, and reduce the risk of death. Commonly used Heart Failure Drugs include ACE inhibitors, beta blockers, diuretics, and angiotensin receptor blockers. These drugs work by reducing the workload on the heart, improving blood flow, and reducing fluid buildup in the body.
Some companies in the Heart Failure Drug market include Pfizer, Novartis, Merck, Sanofi, and Bristol-Myers Squibb. Show Less Read more
